Patents by Inventor Brian McGuinness

Brian McGuinness has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190254816
    Abstract: Methods of transcatheter delivery of a prosthetic heart valve. A distal region of a guide member assembly is advanced into a heart of a patient. The distal region is docked to native anatomy of the heart. A delivery device, including a collapsed prosthetic heart valve, is advanced over the docked guide member assembly. The collapsed prosthetic heart valve is located at an implantation site. The prosthetic heart valve is deployed from the delivery device, and then the delivery device is removed from the patient. At least a portion of the guide member assembly is removed from the patient. In some embodiments, the docking structure is docked to one or more of native mitral valve leaflets, chordae in the left ventricle, or walls of the left ventricle as part of a transseptal mitral valve delivery procedure.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 22, 2019
    Applicant: Medtronic Vascular, Inc.
    Inventors: Marc A. Anderson, Grainne Teresa Carroll, Paul Devereux, Niall Duffy, Matthew Fleming, Alexander J. Hill, Elliot J. Howard, James R. Keogh, Marian Patricia Lally, Luke Lehmann, Jeffrey Madden, Kevin M. Mauch, Ciaran McGuinness, Brian T. McHenry, Karl L. Olney, Geoffrey Orth, Edward Sarnowski, Elizabeth A. Schotzko, Benjamin Wong
  • Publication number: 20190144561
    Abstract: The invention relates to chimeric antigen receptors (CAR) that comprise one or more single human variable domain antibody and cells that express such CAR. In particular, the invention relates to CARs that include multiple single human variable domain antibodies. In a particular embodiment, the one or more single human variable domain antibody binds to prostate membrane antigen.
    Type: Application
    Filed: May 8, 2017
    Publication date: May 16, 2019
    Inventors: Brian McGuinness, Colette Johnston
  • Publication number: 20190023807
    Abstract: The disclosure relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Inventors: Eleanora Balloi, Normann Goodwin, Brian McGuinness, Chris Rossat, Thomas Sandal, Lorraine Thompson
  • Publication number: 20180362666
    Abstract: The invention relates to nucleic acid constructs for expression in mice for the production of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.
    Type: Application
    Filed: October 22, 2014
    Publication date: December 20, 2018
    Applicant: Crescendo Biologics Limited
    Inventors: Yumin Teng, Joyce Young, Brian McGuinness, Mike Romanos, Marianne Brueggemann
  • Publication number: 20180215829
    Abstract: Binding molecules that bind specifically to IL-17RA. The binding molecules are useful in the treatment of disease, for example psoriasis.
    Type: Application
    Filed: January 12, 2016
    Publication date: August 2, 2018
    Inventors: Bryan EDWARDS, Ulla LASHMAR, Brian MCGUINNESS, Mike ROMANOS, Thomas SANDAL, Joyce Young
  • Publication number: 20180118820
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 3, 2018
    Inventors: Bryan EDWARDS, Ulla LASHMAR, Brian MCGUINNESS, Mike ROMANOS, Thomas SANDAL, Yumin TENG
  • Publication number: 20080058343
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
    Type: Application
    Filed: July 12, 2007
    Publication date: March 6, 2008
    Inventors: Stuart Rosenblum, Joseph Kozlowski, Neng-Yang Shih, Brian McGuinness, Douglas Hobbs
  • Publication number: 20080039474
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1. or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
    Type: Application
    Filed: March 19, 2007
    Publication date: February 14, 2008
    Inventors: STUART ROSENBLUM, Joseph Kozlowski, Neng-Yang Shih, Brian McGuinness, Douglas Hobbs
  • Publication number: 20070249813
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: April 17, 2007
    Publication date: October 25, 2007
    Inventors: Jochen Salfeld, Deborah Allen, Hendricus Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John Mankovich, Brian McGuinness, Andrew Roberts, Paul Sakorafas, David Schoenhaut, Tristan Vaughan, Michael White, Alison Wilton
  • Publication number: 20070054919
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
    Type: Application
    Filed: February 14, 2006
    Publication date: March 8, 2007
    Inventors: Stuart Rosenblum, Seong Kim, Qingbei Zeng, Michael Wong, Gopinadhan Anilkumar, Yueheng Jiang, Wensheng Yu, Joseph Kozlowski, Neng-Yang Shih, Bandarpalle Shankar, Brian McGuinness, Guizhen Dong, Lisa Zawacki, Douglas Hobbs, John Baldwin, Yuefei Shao
  • Publication number: 20070021611
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
    Type: Application
    Filed: February 14, 2006
    Publication date: January 25, 2007
    Inventors: Brian McGuinness, Stuart Rosenblum, Joseph Kozlowski, Gopinadhan Anilkumar, Seong Kim, Neng-Yang Shih, Chung-Her Jenh, Paul Zavodny, Douglas Hobbs, Guizhen Dong, Yuefei Shao, Lisa Zawacki, Cangming Yang, Carolyn Carroll
  • Publication number: 20060276480
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
    Type: Application
    Filed: February 14, 2006
    Publication date: December 7, 2006
    Inventors: Michael Wong, Youheng Shu, Wensheng Yu, Stuart Rosenblum, Joseph Kozlowski, Brian McGuinness, Yuefei Shao, Douglas Hobbs
  • Publication number: 20060276479
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
    Type: Application
    Filed: February 14, 2006
    Publication date: December 7, 2006
    Inventors: Seong Kim, Gopinadhan Anilkumar, Michael Wong, Qingbei Zeng, Stuart Rosenblum, Joseph Kozlowski, Yuefei Shao, Brian McGuinness, Douglas Hobbs
  • Publication number: 20060276448
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
    Type: Application
    Filed: February 14, 2006
    Publication date: December 7, 2006
    Inventors: Qingbei Zeng, De-Yi Yang, Stuart Rosenblum, Michael Wong, Gopinadhan Anilkumar, Seong Kim, Wensheng Yu, Joseph Kozlowski, Neng-Yang Shih, Brian McGuinness, Lisa Guise-Zawacki, Doublas Hobbs
  • Publication number: 20060276457
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
    Type: Application
    Filed: February 14, 2006
    Publication date: December 7, 2006
    Inventors: Wensheng Yu, Seong Kim, Gopinadhan Anilkumar, Stuart Rosenblum, Bandarpalle Shankar, Brian McGuinness, Douglas Hobbs, Yuefei Shao
  • Publication number: 20060217392
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prod rug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
    Type: Application
    Filed: February 14, 2006
    Publication date: September 28, 2006
    Inventors: Gopinadhan Anilkumar, Qingbei Zeng, Stuart Rosenblum, Joseph Kozlowski, Brian McGuinness, Douglas Hobbs
  • Publication number: 20060024293
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: September 21, 2005
    Publication date: February 2, 2006
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Jochen Salfeld, Deborah Allen, Hendricus Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John Mankovich, Brian McGuinness, Andrew Roberts, Paul Sakorafas, David Schoenhaut, Tristan Vaughan, Michael White, Alison Wilton